Opportunities Preloader

Please Wait.....

Report

Immunotherapy Drugs Market Report by Drug Type (Monoclonal Antibodies, Vaccines, Interferons Alpha and Beta, Interleukins), Therapy Area (Cancer, Autoimmune and Inflammatory Diseases, Infectious Diseases, and Others), End User (Hospitals, Clinics, and Others), and Region 2024-2032

Market Report I 2024-03-02 I 146 Pages I IMARC Group

The global immunotherapy drugs market size reached US$ 213.0 Billion in 2023. Looking forward, IMARC Group expects the market to reach US$ 425.5 Billion by 2032, exhibiting a growth rate (CAGR) of 7.75% during 2024-2032. The growing prevalence of different cancer types due to the aging population, rising demand for personalized medicines, and the increasing awareness among individuals about early detection and treatment are some of the major factors propelling the market.

Immunotherapy drugs are medical treatments designed to utilize or modify the immune system to fight or control diseases. They focus on specific cells and proteins and aid in minimizing harm to healthy tissues. They reduce the likelihood of developing resistance, offer better outcomes, and have fewer side effects as compared to other treatments. They are utilized in treating various types of cancers, including melanoma, lung, and breast cancer. They are also used in managing specific allergic reactions and treating diseases like rheumatoid arthritis, lupus, and multiple sclerosis. Besides this, as they are effective in controlling chronic inflammatory diseases, the demand for immunotherapy drugs is increasing across the globe.

The rise in the pharmaceutical industry and the expansion of pharmacies worldwide is offering a favorable market outlook. Moreover, strategic collaborations and mergers and acquisitions (M&A) between biotech firms, pharmaceutical companies, and research institutions are supporting the research, development, and commercialization activities of immunotherapy products. Furthermore, the integration of artificial intelligence (AI) and big data analytics in research and development (R&D) activities is enhancing efficiency and precision. This technological integration is enabling the rapid identification of targets, optimization of clinical trials, and prediction of patient responses.

Immunotherapy Drugs Market Trends/Drivers:
The increasing prevalence of target diseases

The rising occurrence of different types of cancer due to lifestyle changes and unhealthy dietary patterns is catalyzing the demand for innovative and effective treatments like immunotherapy is growing. Additionally, the early detection and need for personalized therapy options are encouraging patients and healthcare providers to adopt these advanced treatment alternatives. Apart from this, rapid urbanization and rising pollution levels due to harmful vehicular emissions are resulting in various chronic diseases, which is creating new opportunities for immunotherapy treatments. Furthermore, the increasing aging population, which is highly susceptible to tumor, cancer, and other health conditions, is driving the need for effective treatments and technologies, like immunotherapy drugs.

Adoption of personalized medicines

The increasing utilization of personalized medicines in various medical fields to promote a more patient-centered approach is positively influencing the market. Additionally, the development of advanced diagnostic tools, such as next-generation sequencing and biomarker analysis, is enabling the precise identification of patients for specific immunotherapies. These advancements in diagnostics facilitate early intervention and allow for personalized treatment plans, which aid in enhancing the overall effectiveness of immunotherapy. Apart from this, personalized immunotherapies reduce the likelihood of trial-and-error approaches. Furthermore, this targeted approach minimizes the use of ineffective treatments, avoids unnecessary side effects, facilitates quicker recoveries, and reduces healthcare costs, which is contributing to market growth.

Governmental and regulatory support

Governments and regulatory bodies of various countries are continuously focusing on the development of immunotherapy drugs and therapies, which is offering a favorable market outlook. Additionally, they are providing financial support for conducting the in-depth studies required to develop novel immunotherapies and optimize existing ones. Apart from this, partnerships between governments, research institutions, and private companies are supporting market growth. These collaborations facilitate knowledge exchange and accelerate the development of groundbreaking immunotherapy treatments across borders. Furthermore, the introduction of several supportive governmental healthcare policies is encouraging the adoption and reimbursement of immunotherapies.

Immunotherapy Drugs Industry Segmentation:
IMARC Group provides an analysis of the key trends in each segment of the global immunotherapy drugs market report, along with forecasts at the global, regional and country levels from 2024-2032. Our report has categorized the market based on drug type, therapy area and end user.

Breakup by Drug Type:

Monoclonal Antibodies
Vaccines
Interferons Alpha and Beta
Interleukins

Monoclonal antibodies represent the largest market segment

A detailed breakup and analysis of the market based on the drug type has also been provided in the report. This includes monoclonal antibodies, vaccines, interferons alpha and beta, and interleukins. According to the report, monoclonal antibodies accounted for the largest market share. These antibodies offer a highly specific and targeted approach. They are designed to attach distinct proteins and receptors on the surface of diseased cells, enabling precise intervention. Additionally, regulatory bodies support monoclonal antibody therapies, providing streamlined approval processes and encouraging rapid development and commercialization. Apart from this, ongoing research and investment into the development of monoclonal antibodies contribute to their dominant position in the market. Furthermore, increasing funding and collaboration within the scientific community continue to yield innovative solutions. Moreover, technological advancements in manufacturing processes are making the production of monoclonal antibodies more scalable and cost-effective.

Breakup by Therapy Area:

Cancer
Autoimmune and Inflammatory Diseases
Infectious Diseases
Others

Cancer accounts for the majority of the market share

The report has provided a detailed breakup and analysis of the market based on the therapy area. This includes cancer, autoimmune and inflammatory diseases, infectious diseases, and others. According to the report, cancer represented the largest segment. The rising prevalence of cancer due to the aging population, lifestyle changes, and environmental factors represent one of the key factors positively influencing the market. Additionally, the growing awareness among individuals about the benefits of early diagnosis and treatment of cancer is catalyzing the demand for immunotherapy drugs. Immunotherapy offers targeted treatments that can identify and attack specific cancer cells, minimizing damage to healthy tissue, enhancing effectiveness, and reducing side effects. Apart from this, continuous investments from governmental bodies, private sectors, and philanthropic organizations are supporting cancer research, including the development of immunotherapies, which is offering a favorable market outlook. Furthermore, rising partnerships between pharmaceutical companies, research institutions, and healthcare providers are accelerating the development and accessibility of cancer immunotherapies.

Breakup by End User:

Hospitals
Clinics
Others

Hospitals hold the majority of the market share

A detailed breakup and analysis of the market based on the end user has also been provided in the report. This includes hospitals, clinics, and others. According to the report, hospitals hold the largest market share. Hospitals have a multidisciplinary team of specialists, including oncologists, immunologists, pharmacists, and nurses. These integrated teams enable a collaborative approach to patient care, ensuring the appropriate application and monitoring of immunotherapies. Additionally, they are equipped with state-of-the-art medical technologies and equipment. This access allows for the utilization of advanced immunotherapies. Apart from this, collaborations with pharmaceutical companies allow hospitals to gain early access to new immunotherapy drugs and technologies. These partnerships enhance the ability of hospitals to offer cutting-edge treatment options. Furthermore, they have established relationships with insurance providers and a better understanding of reimbursement policies. Moreover, many hospitals are involved in clinical trials and research collaborations, actively contributing to the advancement of immunotherapy.

Breakup by Region:
North America
United States
Canada
Asia-Pacific
China
Japan
India
South Korea
Australia
Indonesia
Others
Europe
Germany
France
United Kingdom
Italy
Spain
Russia
Others
Latin America
Brazil
Mexico
Others
Middle East and Africa

North America exhibits a clear dominance, accounting for the largest immunotherapy drugs market share

The report has also provided a comprehensive analysis of all the major regional markets, which include North America (the United States and Canada); Europe (Germany, France, the United Kingdom, Italy, Spain, Russia, and others); Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, and others); Latin America (Brazil, Mexico, and others); and the Middle East and Africa. According to the report, North America accounted for the largest market share as the region has a well-established healthcare infrastructure that allows for the efficient distribution and utilization of immunotherapy drugs. Sophisticated medical facilities and well-trained healthcare professionals facilitate the widespread adoption of these treatments. Additionally, the region witnesses substantial investments from public and private sectors in healthcare and biotechnology, which facilitates research, drug development, and commercialization of immunotherapy products. Apart from this, the regulatory bodies in North America, such as the Food and Drug Administration (FDA), offer a conducive environment for drug approval. Furthermore, strategic collaborations between academia, biotech firms, and pharmaceutical companies ensure a dynamic environment for continuous innovation and growth in the field of immunotherapy.

Competitive Landscape:
Companies are actively engaged in various activities to stay competitive and innovate. They are conducting extensive research and development (R&D) activities, working on discovering new targets and optimizing existing therapies. Additionally, these companies are forming strategic partnerships with academic institutions, leveraging their expertise to fuel innovation. Apart from this, they are investing in cutting-edge manufacturing technologies to produce immunotherapy drugs efficiently and at scale. Furthermore, regulatory teams within these companies are collaborating with governmental bodies to ensure compliance with emerging rules and gain expedited approvals for novel treatment. Moreover, many companies are actively participating in international conferences and symposia, sharing knowledge, and learning from global peers.

The report has provided a comprehensive analysis of the competitive landscape in the market. Detailed profiles of all major companies have also been provided. Some of the key players in the market include:

AstraZeneca plc
Bayer AG
Boehringer Ingelheim International GmbH
Bristol-Myers Squibb Company
F. Hoffmann-La Roche AG
GSK plc
Merck & Co. Inc.
Pfizer Inc.
Sanofi S.A.

Recent Developments:
In January 2022, Pfizer Inc. and BioNTech SE entered a strategic collaboration to develop an mRNA-based vaccine to prevent shingles.
In March 2023. Sanofi S.A. announced that it has received marketing authorization for Dupixent (dupilumab), the first biologic medicine for the treatment of moderate-to-severe atopic dermatitis in children.
In January 2021, Enara Bio and Boehringer Ingelheim International GmbH announced a strategic collaboration and licensing agreement for the research and development (R&D) of novel targeted cancer immunotherapy.

Key Questions Answered in This Report

1. How big is the global immunotherapy drugs market?
2. What is the expected growth rate of the global immunotherapy drugs market during 2024-2032?
3. What are the key factors driving the global immunotherapy drugs market?
4. What has been the impact of COVID-19 on the global immunotherapy drugs market?
5. What is the breakup of the global immunotherapy drugs market based on the drug type?
6. What is the breakup of the global immunotherapy drugs market based on the therapy area?
7. What is the breakup of the global immunotherapy drugs market based on the end user?
8. What are the key regions in the global immunotherapy drugs market?
9. Who are the key players/companies in the global immunotherapy drugs market?

1 Preface
2 Scope and Methodology
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 Executive Summary
4 Introduction
4.1 Overview
4.2 Key Industry Trends
5 Global Immunotherapy Drugs Market
5.1 Market Overview
5.2 Market Performance
5.3 Impact of COVID-19
5.4 Market Forecast
6 Market Breakup by Drug Type
6.1 Monoclonal Antibodies
6.1.1 Market Trends
6.1.2 Market Forecast
6.2 Vaccines
6.2.1 Market Trends
6.2.2 Market Forecast
6.3 Interferons Alpha and Beta
6.3.1 Market Trends
6.3.2 Market Forecast
6.4 Interleukins
6.4.1 Market Trends
6.4.2 Market Forecast
7 Market Breakup by Therapy Area
7.1 Cancer
7.1.1 Market Trends
7.1.2 Market Forecast
7.2 Autoimmune and Inflammatory Diseases
7.2.1 Market Trends
7.2.2 Market Forecast
7.3 Infectious Diseases
7.3.1 Market Trends
7.3.2 Market Forecast
7.4 Others
7.4.1 Market Trends
7.4.2 Market Forecast
8 Market Breakup by End User
8.1 Hospitals
8.1.1 Market Trends
8.1.2 Market Forecast
8.2 Clinics
8.2.1 Market Trends
8.2.2 Market Forecast
8.3 Others
8.3.1 Market Trends
8.3.2 Market Forecast
9 Market Breakup by Region
9.1 North America
9.1.1 United States
9.1.1.1 Market Trends
9.1.1.2 Market Forecast
9.1.2 Canada
9.1.2.1 Market Trends
9.1.2.2 Market Forecast
9.2 Asia-Pacific
9.2.1 China
9.2.1.1 Market Trends
9.2.1.2 Market Forecast
9.2.2 Japan
9.2.2.1 Market Trends
9.2.2.2 Market Forecast
9.2.3 India
9.2.3.1 Market Trends
9.2.3.2 Market Forecast
9.2.4 South Korea
9.2.4.1 Market Trends
9.2.4.2 Market Forecast
9.2.5 Australia
9.2.5.1 Market Trends
9.2.5.2 Market Forecast
9.2.6 Indonesia
9.2.6.1 Market Trends
9.2.6.2 Market Forecast
9.2.7 Others
9.2.7.1 Market Trends
9.2.7.2 Market Forecast
9.3 Europe
9.3.1 Germany
9.3.1.1 Market Trends
9.3.1.2 Market Forecast
9.3.2 France
9.3.2.1 Market Trends
9.3.2.2 Market Forecast
9.3.3 United Kingdom
9.3.3.1 Market Trends
9.3.3.2 Market Forecast
9.3.4 Italy
9.3.4.1 Market Trends
9.3.4.2 Market Forecast
9.3.5 Spain
9.3.5.1 Market Trends
9.3.5.2 Market Forecast
9.3.6 Russia
9.3.6.1 Market Trends
9.3.6.2 Market Forecast
9.3.7 Others
9.3.7.1 Market Trends
9.3.7.2 Market Forecast
9.4 Latin America
9.4.1 Brazil
9.4.1.1 Market Trends
9.4.1.2 Market Forecast
9.4.2 Mexico
9.4.2.1 Market Trends
9.4.2.2 Market Forecast
9.4.3 Others
9.4.3.1 Market Trends
9.4.3.2 Market Forecast
9.5 Middle East and Africa
9.5.1 Market Trends
9.5.2 Market Breakup by Country
9.5.3 Market Forecast
10 SWOT Analysis
10.1 Overview
10.2 Strengths
10.3 Weaknesses
10.4 Opportunities
10.5 Threats
11 Value Chain Analysis
12 Porters Five Forces Analysis
12.1 Overview
12.2 Bargaining Power of Buyers
12.3 Bargaining Power of Suppliers
12.4 Degree of Competition
12.5 Threat of New Entrants
12.6 Threat of Substitutes
13 Price Analysis
14 Competitive Landscape
14.1 Market Structure
14.2 Key Players
14.3 Profiles of Key Players
14.3.1 AstraZeneca plc
14.3.1.1 Company Overview
14.3.1.2 Product Portfolio
14.3.1.3 Financials
14.3.1.4 SWOT Analysis
14.3.2 Bayer AG
14.3.2.1 Company Overview
14.3.2.2 Product Portfolio
14.3.2.3 Financials
14.3.2.4 SWOT Analysis
14.3.3 Boehringer Ingelheim International GmbH
14.3.3.1 Company Overview
14.3.3.2 Product Portfolio
14.3.4 Bristol-Myers Squibb Company
14.3.4.1 Company Overview
14.3.4.2 Product Portfolio
14.3.4.3 Financials
14.3.4.4 SWOT Analysis
14.3.5 F. Hoffmann-La Roche AG
14.3.5.1 Company Overview
14.3.5.2 Product Portfolio
14.3.5.3 Financials
14.3.6 GSK plc
14.3.6.1 Company Overview
14.3.6.2 Product Portfolio
14.3.6.3 Financials
14.3.6.4 SWOT Analysis
14.3.7 Merck & Co. Inc.
14.3.7.1 Company Overview
14.3.7.2 Product Portfolio
14.3.7.3 Financials
14.3.7.4 SWOT Analysis
14.3.8 Pfizer Inc.
14.3.8.1 Company Overview
14.3.8.2 Product Portfolio
14.3.8.3 Financials
14.3.8.4 SWOT Analysis
14.3.9 Sanofi S.A.
14.3.9.1 Company Overview
14.3.9.2 Product Portfolio
14.3.9.3 Financials
14.3.9.4 SWOT Analysis
Kindly, note that this only represents a partial list of companies, and the complete list has been provided in the report.

Figure 1: Global: Immunotherapy Drugs Market: Major Drivers and Challenges
Figure 2: Global: Immunotherapy Drugs Market: Sales Value (in Billion US$), 2018-2023
Figure 3: Global: Immunotherapy Drugs Market Forecast: Sales Value (in Billion US$), 2024-2032
Figure 4: Global: Immunotherapy Drugs Market: Breakup by Type (in %), 2023
Figure 5: Global: Immunotherapy Drugs Market: Breakup by Therapy Area (in %), 2023
Figure 6: Global: Immunotherapy Drugs Market: Breakup by End User (in %), 2023
Figure 7: Global: Immunotherapy Drugs Market: Breakup by Region (in %), 2023
Figure 8: Global: Immunotherapy Drugs (Monoclonal Antibodies) Market: Sales Value (in Million US$), 2018 & 2023
Figure 9: Global: Immunotherapy Drugs (Monoclonal Antibodies) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 10: Global: Immunotherapy Drugs (Vaccines) Market: Sales Value (in Million US$), 2018 & 2023
Figure 11: Global: Immunotherapy Drugs (Vaccines) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 12: Global: Immunotherapy Drugs (Interferons Alpha and Beta) Market: Sales Value (in Million US$), 2018 & 2023
Figure 13: Global: Immunotherapy Drugs (Interferons Alpha and Beta) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 14: Global: Immunotherapy Drugs (Interleukins) Market: Sales Value (in Million US$), 2018 & 2023
Figure 15: Global: Immunotherapy Drugs (Interleukins) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 16: Global: Immunotherapy Drugs (Cancer) Market: Sales Value (in Million US$), 2018 & 2023
Figure 17: Global: Immunotherapy Drugs (Cancer) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 18: Global: Immunotherapy Drugs (Autoimmune and Inflammatory Diseases) Market: Sales Value (in Million US$), 2018 & 2023
Figure 19: Global: Immunotherapy Drugs (Autoimmune and Inflammatory Diseases) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 20: Global: Immunotherapy Drugs (Infectious Diseases) Market: Sales Value (in Million US$), 2018 & 2023
Figure 21: Global: Immunotherapy Drugs (Infectious Diseases) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 22: Global: Immunotherapy Drugs (Other Therapy Areas) Market: Sales Value (in Million US$), 2018 & 2023
Figure 23: Global: Immunotherapy Drugs (Other Therapy Areas) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 24: Global: Immunotherapy Drugs (Hospitals) Market: Sales Value (in Million US$), 2018 & 2023
Figure 25: Global: Immunotherapy Drugs (Hospitals) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 26: Global: Immunotherapy Drugs (Clinics) Market: Sales Value (in Million US$), 2018 & 2023
Figure 27: Global: Immunotherapy Drugs (Clinics) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 28: Global: Immunotherapy Drugs (Other End Users) Market: Sales Value (in Million US$), 2018 & 2023
Figure 29: Global: Immunotherapy Drugs (Other End Users) Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 30: North America: Immunotherapy Drugs Market: Sales Value (in Million US$), 2018 & 2023
Figure 31: North America: Immunotherapy Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 32: United States: Immunotherapy Drugs Market: Sales Value (in Million US$), 2018 & 2023
Figure 33: United States: Immunotherapy Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 34: Canada: Immunotherapy Drugs Market: Sales Value (in Million US$), 2018 & 2023
Figure 35: Canada: Immunotherapy Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 36: Asia-Pacific: Immunotherapy Drugs Market: Sales Value (in Million US$), 2018 & 2023
Figure 37: Asia-Pacific: Immunotherapy Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 38: China: Immunotherapy Drugs Market: Sales Value (in Million US$), 2018 & 2023
Figure 39: China: Immunotherapy Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 40: Japan: Immunotherapy Drugs Market: Sales Value (in Million US$), 2018 & 2023
Figure 41: Japan: Immunotherapy Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 42: India: Immunotherapy Drugs Market: Sales Value (in Million US$), 2018 & 2023
Figure 43: India: Immunotherapy Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 44: South Korea: Immunotherapy Drugs Market: Sales Value (in Million US$), 2018 & 2023
Figure 45: South Korea: Immunotherapy Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 46: Australia: Immunotherapy Drugs Market: Sales Value (in Million US$), 2018 & 2023
Figure 47: Australia: Immunotherapy Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 48: Indonesia: Immunotherapy Drugs Market: Sales Value (in Million US$), 2018 & 2023
Figure 49: Indonesia: Immunotherapy Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 50: Others: Immunotherapy Drugs Market: Sales Value (in Million US$), 2018 & 2023
Figure 51: Others: Immunotherapy Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 52: Europe: Immunotherapy Drugs Market: Sales Value (in Million US$), 2018 & 2023
Figure 53: Europe: Immunotherapy Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 54: Germany: Immunotherapy Drugs Market: Sales Value (in Million US$), 2018 & 2023
Figure 55: Germany: Immunotherapy Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 56: France: Immunotherapy Drugs Market: Sales Value (in Million US$), 2018 & 2023
Figure 57: France: Immunotherapy Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 58: United Kingdom: Immunotherapy Drugs Market: Sales Value (in Million US$), 2018 & 2023
Figure 59: United Kingdom: Immunotherapy Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 60: Italy: Immunotherapy Drugs Market: Sales Value (in Million US$), 2018 & 2023
Figure 61: Italy: Immunotherapy Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 62: Spain: Immunotherapy Drugs Market: Sales Value (in Million US$), 2018 & 2023
Figure 63: Spain: Immunotherapy Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 64: Russia: Immunotherapy Drugs Market: Sales Value (in Million US$), 2018 & 2023
Figure 65: Russia: Immunotherapy Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 66: Others: Immunotherapy Drugs Market: Sales Value (in Million US$), 2018 & 2023
Figure 67: Others: Immunotherapy Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 68: Latin America: Immunotherapy Drugs Market: Sales Value (in Million US$), 2018 & 2023
Figure 69: Latin America: Immunotherapy Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 70: Brazil: Immunotherapy Drugs Market: Sales Value (in Million US$), 2018 & 2023
Figure 71: Brazil: Immunotherapy Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 72: Mexico: Immunotherapy Drugs Market: Sales Value (in Million US$), 2018 & 2023
Figure 73: Mexico: Immunotherapy Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 74: Others: Immunotherapy Drugs Market: Sales Value (in Million US$), 2018 & 2023
Figure 75: Others: Immunotherapy Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 76: Middle East and Africa: Immunotherapy Drugs Market: Sales Value (in Million US$), 2018 & 2023
Figure 77: Middle East and Africa: Immunotherapy Drugs Market: Breakup by Country (in %), 2023
Figure 78: Middle East and Africa: Immunotherapy Drugs Market Forecast: Sales Value (in Million US$), 2024-2032
Figure 79: Global: Immunotherapy Drugs Industry: SWOT Analysis
Figure 80: Global: Immunotherapy Drugs Industry: Value Chain Analysis
Figure 81: Global: Immunotherapy Drugs Industry: Porter's Five Forces Analysis

Table 1: Global: Immunotherapy Drugs Market: Key Industry Highlights, 2023 & 2032
Table 2: Global: Immunotherapy Drugs Market Forecast: Breakup by Type (in Million US$), 2024-2032
Table 3: Global: Immunotherapy Drugs Market Forecast: Breakup by Therapy Area (in Million US$), 2024-2032
Table 4: Global: Immunotherapy Drugs Market Forecast: Breakup by End User (in Million US$), 2024-2032
Table 5: Global: Immunotherapy Drugs Market Forecast: Breakup by Region (in Million US$), 2024-2032
Table 6: Global: Immunotherapy Drugs Market: Competitive Structure
Table 7: Global: Immunotherapy Drugs Market: Key Players

  • Not Sure / Need Reassuring
    • Confirm Content
      • Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:

        Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.

        Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.

        Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.

    • Sample Pages
      • With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.

        It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.

        To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.

    • Check for Alternatives
      • Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.

        To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.

  • Prices / Formats / Delivery
    • Prices
      • All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.

        Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.

    • Discounts
      • As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.

        Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.

        To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.

    • Available Currencies
      • Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.

        Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.

        To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.

    • Licenses
      • License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.

        If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.

    • Global Site License
      • The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.

        It is important to note that this may exclude Parent Companies or Subsidiaries.

        If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.

    • Formats
      • The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.

        If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.

    • Delivery
      • Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.

        Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.

        If a delay in delivery is expected you will be informed about it immediately.

    • Shipping Charges
      • As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.

        If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.

  • Ordering
    • By Credit Card
      • We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.

        Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.

        For more information on PayU please visit: https://www.payu.pl/en/about-us

    • By Money Transfer
      • If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.

        With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.

  • Security
    • Website security
      • We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.

        Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.

    • Credit Card Security
      • We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.

        PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.

PLEASE SELECT LICENSE
  • $3899.00
  • $4899.00
  • $5899.00
  • ADD TO BASKET
  • BUY NOW